Like MediMedia Pharma Solutions

closed 3/2/2015 via BusinessWire

ICON Plc, acquired MediMedia Pharma Solutions

synopsis: ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries announced that it has completed the acquisition of MediMedia Pharma Solutions. MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets and Complete HealthCare Communications.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development. "
target parent: Vestar Capital Partners
target: MediMedia Pharma Solutions
MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets (MMM) and Complete HealthCare Communications (CHC). MMM is a strategic payer-validated market access solutions for the biopharmaceutical and medical device industries. CHC is a medical communication agency.
price ($mm)
$120
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/3/2015 via BusinessWire

Haymarket Media, LLC, acquired Group DCA

synopsis: Haymarket Media, Inc, a privately owned media company, is pleased to announce the acquisition of Group DCA—an interactive digital communications agency specializing in multi-channel engagement of health care providers—from PDI Inc.
buyer parent: Haymarket Group Limited
buyer: Haymarket Media, LLC
Haymarket Media Group is a privately owned media company. It has publications in the consumer, business, professional and customer sectors, both print and online. It also operates exhibitions allied to its own publications, and on behalf of organisations such as the BBC. "
target parent: PDI, Inc.
target: Group DCA
Group dca offers the creativity and innovation of an interactive agency, combined with the brand-building strategy and skilled account management of an agency of record. Those qualifications translate into award-winning programs powered by DIAGRAM™, their proprietary software.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/4/2010 via PR Newswire

PDI, Inc., acquired Group DCA

synopsis: PDI, Inc., a leading provider of integrated promotional outsource services to health care companies, announced the expansion of its business with the acquisition of Group DCA, a privately held interactive digital communications agency serving biopharmaceutical companies.
buyer: PDI, Inc. (PDII:$140.12)
PDI is a commercial sales and marketing partner to the biopharmaceutical and medical devices & diagnostics industries. "
target: Group DCA
Group DCA, formerly Dot Com Advisors, offers the creativity and innovation of an interactive agency, combined with the brand-building strategy and skilled account management of an agency of record. It is a privately held interactive digital communications agency serving biopharmaceutical companies.
price ($mm)[EV]
$24 [$25]
rev ($mm)
$15
EBITDA ($mm)
EV / rev
3.9x
EV / EBITDA
closed 2/2/2010 via PR Newswire

Advanced Health Media, LLC, acquired Advogent Group, Inc.

synopsis: Advanced Health Media, LLC, the leading U.S. provider of pharmaceutical sales, marketing and compliance technology and services, announced it has acquired substantially all of the assets of Advogent Group, Inc., a provider of marketing services for the pharmaceutical industry.
buyer parent: Arlington Capital Partners
buyer: Advanced Health Media, LLC
Advanced Health Media, Inc. ("AHM") is an all-media medical communications and marketing firm. AHM combines industry experience and technological innovation to supply custom marketing solutions and services to the pharmaceutical industry. "
target parent: Platinum Equity, LLC
target: Advogent Group, Inc.
Advogent delivers promotional and strategic communications, certified education and event data management services, and contract sales services to some of the world’s largest pharmaceutical and biotechnology companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/4/2007 via Company Press Release

MediMedia USA, acquired Complete Healthcare Communications Inc.

synopsis: MediMedia USA announced the acquisition of a majority interest in Complete Healthcare Communications, Inc., a leading strategic medical communications agency that specializes in strategic publication planning. CHC will join the Professional Division of MediMedia USA.
buyer parent: Vestar Capital Partners
buyer: MediMedia USA
MediMedia’s products and services include integrated and comprehensive health management programs, patient education content, and applications purchased by healthcare stakeholders: physicians, patients, employers, hospitals, health plans and pharmaceutical companies. "
target: Complete Healthcare Communications Inc.
Complete Healthcare Communications is a strategic medical communications agency that specializes in publication planning. Our commitment to all of our clients is to deliver the highest product quality coupled with exceptional service, resulting in scientific integrity with commercial impact.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/6/2007 via

Arlington Capital Partners, acquired Advanced Health Media

synopsis: Arlington Capital is near a deal to buy a majority stake in Advanced Health Media, a provider of marketing services and software to pharmaceutical companies, people familiar with the matter said.
buyer: Arlington Capital Partners
Arlington Capital Partners is a private equity firm with over $450 million of committed capital. We are focused on management buyout and late stage expansion equity investment opportunities. Our target is middle-market companies with enterprise values typically between $50 million and $500 million. "
target: Advanced Health Media
Advanced Health Media, Inc. ("AHM") is an all-media medical communications and marketing firm. AHM combines industry experience and technological innovation to supply custom marketing solutions and services to the pharmaceutical industry.
price ($mm)
rev ($mm)
$200
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
announced 1/10/2022 via GlobeNewswire

XpresSpa Group, Inc., will acquire HyperPointe

synopsis: XpresSpa Group, Inc., a travel health and wellness company, announced it had entered into an agreement to acquire all of the equity interests of GCG Connect, LLC d/b/a HyperPointe, a leading digital healthcare and data analytics relationship marketing agency servicing the global healthcare and pharmaceutical industry.
buyer: XpresSpa Group, Inc. (XSPA:$44.69)
XpresSpa Group, Inc. is a leading global health and wellness holding company operating three distinct brands: XpresCheck®, XpresSpa®, Treat™. XpresCheck is a leading on-site airport provider of COVID-19 screening and testing with 14 locations in 12 domestic airports. "
target: HyperPointe
HyperPointe is a leading digital healthcare and data analytics relationship marketing agency servicing the global healthcare and pharmaceutical industry. HyperPointe has significant experience in patient and healthcare professional marketing and deep experience with customer experience management.
price ($mm)
$6.50
rev ($mm)
$6
EBITDA ($mm)
$1
EV / rev
2.5x
EV / EBITDA
11.7x
closed 12/23/2021 via BNC Analysis

Uniphar plc, acquired Events 4 Healthcare Ltd

synopsis: Uniphar PLC has acquired Events4Healthcare (E4H). Events4Healthcare Ltd (E4H) is a U.K. pharmaceutical marketing agency. E4H are experts in virtual solutions, digital meetings, virtual ad boards, e-conferencing, webinars and more.
buyer: Uniphar plc (ISE:UPR:$2,171.45)
Uniphar plc is a trusted global partner to pharma and medtech manufacturers, working to improve patient access to medicines in Europe and around the world. They provide outsourced and specialised services to clients. "
target: Events 4 Healthcare Ltd
Events4Healthcare Ltd (E4H) is a U.K. pharmaceutical marketing agency. E4H are experts in virtual solutions, digital meetings, virtual ad boards, e-conferencing, webinars and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/10/2015 via BusinessWire

Accenture, acquired Boomerang Pharmaceutical Communications

synopsis: Accenture, a leading global professional services company, announced its acquisition of Boomerang Pharmaceutical Communications, an international full-service digital marketing agency serving the pharmaceutical, biotech and medical-device industries.
buyer: Accenture (ACN:$53,736.36)
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Accenture works at the intersection of business and technology to help clients improve their performance. "
target: Boomerang Pharmaceutical Communications
Boomerang Pharmaceutical Communications provides digital marketing services, web-site development and site promotion for the pharmaceutical and healthcare industry. They marry the art of creativity with the rigor of science to produce digital solutions for pharmaceutical and biotech clients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/13/2015 via PR Newswire

Havas Health, acquired Bird & Schulte Advertising

synopsis: The Havas Group has acquired Bird & Schulte Advertising, an award-winning agency based in Germany. Bird & Schulte offers a full spectrum of services for Rx and OTC, including advertising, digital media, events and medical education. Bird & Schulte will be renamed Havas Life Bird & Schulte, part of the Havas Health global network.
buyer parent: Havas
buyer: Havas Health
Havas Health is one of the largest fully integrated, global health communications groups. With 60 health-focused offices in over 50 countries, they offer advertising, public relations, event promotion, medical education, digital marketing, direct-to-patient and consulting services. "
target: Bird & Schulte Advertising
Bird & Schulte, a full-service health and wellness communications agency, offers the complete spectrum covering advertising, medical education, events and digital media for Rx and OTC.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/7/2014 via PR Newswire

Cognizant Technology Solutions, acquired Cadient Group

synopsis: Cognizant announced it has acquired Cadient Group, a full-service digital marketing agency that serves a broad spectrum of life sciences companies in the pharmaceutical, biotechnology, consumer health, and medical device industries.
buyer: Cognizant Technology Solutions (CTSH:$17,914.00)
Cognizant is a leading provider of information technology, consulting, and business process outsourcing services, dedicated to helping the world's leading companies build stronger businesses. "
target parent: Edison Partners
target: Cadient Group
Cadient Group is a leading digital marketing agency that serves a diverse range of industry markets and stakeholders, including pharmaceuticals, biotechnology, medical devices, hospital and healthcare systems, institutions and associations.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/9/2012 via

Indegene Lifesystems Pvt Ltd., will acquire Aptilon Holdings Inc

synopsis: Indegene Lifesystems Pvt. Ltd., a leading provider of R&D, commercial and marketing solutions to top global pharmaceutical and healthcare organizations, announced a definitive agreement to acquire the multi-channel, video and e-detailing, and physician marketing services business of Aptilon Holdings Inc.
buyer: Indegene Lifesystems Pvt Ltd.
Indegene Lifesystems is a global provider of knowledge-intensive services that span a full spectrum of integrated scientific promotions, medical education, and business analytical solutions for pharmaceutical, medical device, and health care organizations. "
target: Aptilon Holdings Inc
Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach, message, connect, and interact with US physicians and healthcare professionals via multiple access channels.
price ($mm)
$1.51
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/5/2012 via PR Newswire

inVentiv Health, Inc., acquired Kazaam Interactive

synopsis: inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced that it has acquired Kazaam Interactive, a full-service interactive agency providing comprehensive solutions and services for healthcare agencies and brands.
buyer parent: Thomas H. Lee Partners, L.P.
buyer: inVentiv Health, Inc.
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. "
target: Kazaam Interactive
Kazaam is a full-service digital marketing agency offering premier digital strategy and solutions to brands and organizations. The company has worked with over sixty of the world's largest brands and brings a real-world understanding for utilizing the online channels.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/22/2018 via Company Press Release

Clanwilliam Group Ltd., acquired Obsidian Healthcare Group

synopsis: Clanwilliam Group, a Dublin-based company that develops, sells and integrates technology solutions to the Private Consultant and pharmacy communities, acquired Obsidian Healthcare, a UK full service global healthcare communications Group that delivers medical communications activities and continuing medical education programs.
buyer parent: Eli Global, LLC
buyer: Clanwilliam Group Ltd.
Clanwilliam Group, headquartered in Dublin, is an expanding healthcare, technology and services business. They develop, sell and integrate a range of technology solutions and services predominately to the GP, Private Consultant and pharmacy communities. "
target: Obsidian Healthcare Group
Headquartered in the UK, Obsidian Healthcare Group is a full service, global healthcare communications Group with two distinct firewalled divisions, allowing it to deliver collaboratively sponsored medical communications activities and medical education and continuing medical education programs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/3/2020 via Company Press Release

Healthware Group S.r.l., acquired Pharmaphorum

synopsis: Healthware Group has acquired pharmaphorum in a move that will combine its consulting and full-service agency capabilities with pharmaphorum’s content-driven stakeholder engagement and publications. Pharmaphorum combines industry leading publications, strategic consulting and a content-driven stakeholder engagement agency.
buyer: Healthware Group S.r.l.
Healthware is a next-generation integrated consulting group that has been supporting marketing and sales in life sciences through its full-service agency for more than 20 years. "
target: Pharmaphorum
Pharmaphorum combines industry leading publications, strategic consulting and a content-driven stakeholder engagement agency. Pharmaphorum supports clients through their publication and consultative and creative capabilities in marketing, medical, communications and digital innovation.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/18/2022 via BNC Analysis

Ashfield Engage, acquired Propensity4

synopsis: Ashfield Engage has acquired PROPENSITY4, a smart data organization and leader in the healthcare insights and analytics arena, which integrates internal and external data assets and applies the right methodologies to derive detailed insight using proprietary analytical platforms that enables data-performance driven strategy.
buyer parent: UDG Healthcare plc
buyer: Ashfield Engage
Ashfield Engage is an expert, global partner in strategic engagement and execution. Ashfield Engage helps clients to communicate with all healthcare audiences to ensure they access knowledge, support, and medicines when and where they need them. "
target: Propensity4
PROPENSITY4 is an integrated data and insight solutions provider serving the pharmaceutical and biotechnology industry. The organization started in 2011 with the primary value proposition to bridge data and insight integration gaps amongst analytic vendors in the life-science industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/20/2017 via BNC Analysis

UDG Healthcare plc, acquired MicroMass Communications, Inc.

synopsis: UDG Healthcare, an international healthcare services provider, announced the acquisition of MicroMass Communications, a U.S.-based healthcare communications agency specializing in behavioural change.
buyer: UDG Healthcare plc (LSE:UDG:$1,298.52)
UDG Healthcare plc is a leading international partner of choice delivering clinical, commercial, communication and packaging services to the healthcare industry, employing 8,000 with operations in 23 countries and delivering services in over 50 countries. "
target parent: Periscope Equity
target: MicroMass Communications, Inc.
MicroMass Communications is a healthcare marketing agency specializing in digital, relationship marketing, and non-personal promotion. Their unique expertise in human health behavior allows them to create highly effective solutions for patients and health care providers.
price ($mm)
$64
rev ($mm)
$23
EBITDA ($mm)
EV / rev
3.3x
EV / EBITDA
closed 4/2/2012 via GlobeNewswire

Paul Werth Associates, acquired Generations Sync

synopsis: Paul Werth Associates, an integrated communications firm based in Columbus, Ohio, has acquired Generations Sync, a Chicago-based boutique firm specializing in health care public relations and direct marketing. Generations Sync is immediately changing its name to Paul Werth Associates.
buyer: Paul Werth Associates
Paul Werth Associates is an independent, full-service communications firm that helps grow businesses, launch brands and shape strategies for some of the Midwest's leading organizations. Its competencies include public relations, public affairs, marketing and branding, B2B advertising, and research. "
target: Generations Sync
Generations Sync is a boutique firm specializing in health care public relations and direct marketing. It produces stronger brands and loyal customers by integrating emerging technologies with traditional disciplines such as strategy, promotional education, and direct marketing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/2/2022 via BNC Analysis

M3.com, acquired MirVracha LCC

synopsis: M3, Japan's largest portal site dedicated to healthcare professionals, has acquired MirVracha, which operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies.
buyer: M3.com (TSE:2413:$1,724.14)
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries. "
target: MirVracha LCC
MirVracha operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/23/2020 via BNC Analysis

Relevate Health Group, acquired Arteric

synopsis: Relevate Health Group, a healthcare marketing agency, has acquired Arteric, a digital healthcare marketing agency. Arteric delivers intelligent solutions that create meaningful engagements across the digital ecosystem. The agency serves leading pharmaceutical brands and offers services for SEO, websites, web apps, marketing strategy, and more.
buyer: Relevate Health Group
Relevate Health Group is a healthcare marketing agency. Relevate Health Group helps hospitals, health systems and life science companies relevantly reach their target audiences. Their award-winning content, strategy and engagement tools help their clients to attract and retain high-value consumers. "
target: Arteric
Arteric is a digital healthcare marketing agency. Arteric delivers intelligent solutions that create meaningful engagements across the digital ecosystem. The agency serves leading pharmaceutical brands and offers services for SEO, websites, web apps, mobile apps, marketing strategy, and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2015 via BusinessWire

ICON Plc, acquired MediMedia Pharma Solutions

synopsis: ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries announced that it has completed the acquisition of MediMedia Pharma Solutions. MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets and Complete HealthCare Communications.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development. "
target parent: Vestar Capital Partners
target: MediMedia Pharma Solutions
MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets (MMM) and Complete HealthCare Communications (CHC). MMM is a strategic payer-validated market access solutions for the biopharmaceutical and medical device industries. CHC is a medical communication agency.
price ($mm)
$120
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/4/2007 via Company Press Release

MediMedia USA, acquired Complete Healthcare Communications Inc.

synopsis: MediMedia USA announced the acquisition of a majority interest in Complete Healthcare Communications, Inc., a leading strategic medical communications agency that specializes in strategic publication planning. CHC will join the Professional Division of MediMedia USA.
buyer parent: Vestar Capital Partners
buyer: MediMedia USA
MediMedia’s products and services include integrated and comprehensive health management programs, patient education content, and applications purchased by healthcare stakeholders: physicians, patients, employers, hospitals, health plans and pharmaceutical companies. "
target: Complete Healthcare Communications Inc.
Complete Healthcare Communications is a strategic medical communications agency that specializes in publication planning. Our commitment to all of our clients is to deliver the highest product quality coupled with exceptional service, resulting in scientific integrity with commercial impact.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2015 via BusinessWire

ICON Plc, acquired MediMedia Pharma Solutions

synopsis: ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries announced that it has completed the acquisition of MediMedia Pharma Solutions. MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets and Complete HealthCare Communications.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development. "
target parent: Vestar Capital Partners
target: MediMedia Pharma Solutions
MediaMedia Pharma Solutions is a combination of MediMedia Managed Markets (MMM) and Complete HealthCare Communications (CHC). MMM is a strategic payer-validated market access solutions for the biopharmaceutical and medical device industries. CHC is a medical communication agency.
price ($mm)
$120
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/14/2011 via BusinessWire

ICON Plc, acquired Firecrest Clinical

synopsis: ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced the acquisition of Firecrest Clinical, a market-leading provider of technology solutions that boost investigator site performance and study management.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development. "
target: Firecrest Clinical
Firecrest definitively improves clinical site performance through e-clinical technology solutions that provide investigator training and study management tools. Firecrest works to increase patient recruitment and produce much cleaner data.
price ($mm)
$24
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2011 via Company Press Release

ICON Plc, acquired Oxford Outcomes

synopsis: ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced the expansion of its Late Phase and Outcomes Research services through the acquisition of Oxford Outcomes, a leading international health outcomes consultancy.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. "
target: Oxford Outcomes
Headquartered in Oxford, UK, and with offices in the USA and Canada, Oxford Outcomes provides specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation.
price ($mm)
$28*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/14/2008 via BusinessWire

ICON Plc, acquired Prevalere Life Sciences, Inc.

synopsis: ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced that is has acquired Prevalere Life Sciences Inc., a wholly owned subsidiary of ORS Labs Inc.
buyer: ICON Plc (ICLR:$1,541.91)
ICON Clinical Research is a full service clinical research organization providing a comprehensive range of clinical services in Phase I-IV clinical trials to the pharmaceutical, biotechnology and device industries. "
target parent: Oneida Research Services, Inc.
target: Prevalere Life Sciences, Inc.
Prevalere Life Sciences, Inc. is a contract research organization providing consulting and GLP/cGMP compliant analytical testing services to meet the research and development challenges of the pharmaceutical and biotechnology industries.
price ($mm)
$38
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (INCR:$4,730.38)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (INCR:$4,730.38)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like MediMedia Pharma Solutions


read more

MediMedia Pharma Solutions

Group DCA

Group DCA

Advogent Group, Inc.

Complete Healthcare Communications Inc.

Advanced Health Media

HyperPointe

Events 4 Healthcare Ltd

Boomerang Pharmaceutical Communications

Bird & Schulte Advertising

Cadient Group

Aptilon Holdings Inc

Kazaam Interactive

Obsidian Healthcare Group

Pharmaphorum

Propensity4

MicroMass Communications, Inc.

Generations Sync

MirVracha LCC

Arteric

read more

MediMedia Pharma Solutions

Complete Healthcare Communications Inc.

read more

MediMedia Pharma Solutions

Firecrest Clinical

Oxford Outcomes

Prevalere Life Sciences, Inc.

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: PDII
 
 
 
 
 
 
 
 
PDI, Inc.
PDI, Inc.
PDI is a leading healthcare commercialization company providing go-to-market strategy and execution to established and emerging pharmaceutical, biotechnology, diagnostics and healthcare companies in the United States.
year
2015
rev ($mm)
$140.12
EBITDA ($mm)
($14.89)
EBIT ($mm)
($19.53)
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: INCR
 
 
 
 
 
 
 
 
Syneos Health
Syneos Health
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Their company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities.
year
2021
rev ($mm)
$4,730.38
EBITDA ($mm)
$633.74
EBIT ($mm)
$407.86
Net Income ($mm)
$235.93
Employees
24310
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: TSXV:IPA
 
 
 
 
 
 
 
 
ImmunoPrecise
ImmunoPrecise
ImmunoPrecise Antibodies (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, DeepDisplay™ custom phage libraries, as well as the Abthena™.
year
2021
rev ($mm)
$14.38
EBITDA ($mm)
($3.69)
EBIT ($mm)
($5.34)
Net Income ($mm)
Employees
73
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: NEO
 
 
 
 
 
 
 
 
NeoGenomics Laboratories
NeoGenomics Laboratories
NeoGenomics is a leading cancer diagnostic reference laboratory. NeoGenomics offers testing services for oncologists, pathologists, and pharmaceutical centers. Their areas of expertise include cancer cytogenetics, hematologic and solid tumor FISH testing, molecular oncology tests, and more.
year
2020
rev ($mm)
$444.45
EBITDA ($mm)
$23.80
EBIT ($mm)
($11.92)
Net Income ($mm)
$4.17
Employees
1700
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2021
rev ($mm)
$16,388.10
EBITDA ($mm)
$4,886.00
EBIT ($mm)
$4,358.30
Net Income ($mm)
$2,878.70
Employees
68780
  • drill down
  • watch